Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Multiple sclerosis: Atacicept increases relapse rates in multiple sclerosis.
LEBER'S DISEASE WITH SYMPTOMS RESEMBLING DISSEMINATED SCLEROSIS.
Multiple sclerosis: Progression rate and severity in a multicenter cohort from Algeria.
The complement cascade: Yin-Yang in neuroinflammation--neuro-protection and -degeneration.
Helminth therapy or elimination: epidemiological, immunological, and clinical considerations.
Clinically Isolated Syndrome Suggestive of Multiple Sclerosis: Dynamic Patterns of Gray and White Matter Changes-A 2-year MR Imaging Study.
Cost-Effectiveness Analysis of Delayed-Release Dimethyl Fumarate for The Treatment of Relapsing Remitting Multiple Sclerosis In Spain.
CD14 is a key organizer of microglial responses to CNS infection and injury.
The diagnosis of multiple sclerosis.
Podoplanin is an inflammatory protein upregulated in Th17 cells in SKG arthritic joints.
Peripheral blood mononuclear cell membrane fluidity and disease outcome in patients with multiple sclerosis.
Avidity of anti-neurocytoskeletal antibodies in cerebrospinal fluid and serum.
Ocular inflammation in neurorheumatic disease.
Cell-based therapy approaches: the hope for incurable diseases.
Clinical correlations of motor and somatosensory evoked potentials in neuromyelitis optica.
Psychosocial, Affective, and Behavioral Consequences of Multiple SclerosisTreatment of the "Whole" Patient.
Multiple sclerosis treatment with natalizumab: analysis of a hospital-based cohort.
A Simple Sign for Recognizing Off-Axis OCT Measurement Beam Placement in the Context of Multicentre Studies.
Lymphocytes with cytotoxic activity induce rapid microtubule axonal destabilization independently and before signs of neuronal death.
Multiple sclerosis in diverse populations: characteristics in distinct Arab ethnicities in Israel.
Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data.
Pilates exercise training vs. physical therapy for improving walking and balance in people with multiple sclerosis: A randomized controlled trial.
Enrichment of Oligodendrocyte Progenitors from Differentiated Neural Precursors by Clonal Sphere Preparations.
Balancing Early Aggression Against Risk of Progression in Multiple Sclerosis.
Mortality and Cause of Death in Multiple Sclerosis: Findings from a Prospective Population-Based Cohort in Bizkaia, Basque Country, Spain.
Pages
« first
‹ previous
…
282
283
284
285
286
287
288
289
290
…
next ›
last »